

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-50. (Canceled)

51. (Currently Amended) An isolated antibody which binds to a human CCR5 chemokine receptor on the surface of a CD4+ cell, wherein the antibody inhibits fusion of a HIV-1, or a HIV-1 infected cell, to the CD4+ cell, so as to thereby inhibit ~~and inhibits~~ HIV-1 infection of such CD4+ cell.

52. (Canceled)

53. (Previously Presented) The antibody of claim 51, wherein the CD4+ cell is a PM-1 cell.

54. (Previously Presented) The antibody of claim 51, wherein the CD4+ cell is a primary CD4+ T-cell.

55. (Previously Presented) The antibody of claim 51, wherein the CD4+ cell is a peripheral blood mononuclear cell (PBMC).

56. (Previously Presented) The antibody of claim 51, wherein the antibody is a monoclonal antibody.

57. (Currently Amended) A pharmaceutical composition comprising the antibody of claim 51 ~~or 56~~ and a pharmaceutically acceptable carrier.

Applicants: Graham P. Allaway et al.

U.S. Serial No.: 09/888,938

Filed: June 25, 2001

Page 3

58. (Previously Presented) The pharmaceutical composition of claim 57, wherein the antibody is present in an amount effective to inhibit HIV-1 infection.
59. (New) A pharmaceutical composition comprising the antibody of claim 56 and a pharmaceutically acceptable carrier.
60. (New) The pharmaceutical composition of claim 59, wherein the antibody is present in an amount effective to inhibit HIV-1 infection.